A scientific introduction to a multi-receptor peptide studied in metabolic research.
Explore its molecular identity, the biology of three related hormone-receptor pathways, and the research questions shaping the field.
Retatrutide, also known by the development code LY3437943, is an investigational synthetic peptide designed to activate three hormone receptors: GIPR, GLP-1R and GCGR.
These receptors participate in interconnected biological systems involved in nutrient sensing, glucose regulation, appetite-related signalling and energy balance. Retatrutide is scientifically notable because a single peptide molecule has activity across all three targets.
This page explains the underlying biology as a research topic. It does not describe a treatment, recommend use, or make claims about individual outcomes.
Retatrutide is described in the scientific literature as a triple agonist. The three receptor systems have distinct biological roles, while also interacting within broader metabolic networks.
GIPR is part of the incretin system activated in response to nutrient intake. Research explores its role in glucose-dependent insulin secretion, adipose-tissue biology and communication among the gut, pancreas and other metabolic tissues.
Nutrient-responsive signallingGLP-1R signalling is studied in glucose-dependent insulin secretion, gastric emptying and neural circuits involved in food intake and satiety. These interconnected pathways are relevant to metabolic biology research.
Glucose and appetite-related signallingGCGR signalling is involved in hepatic glucose output, glycogen metabolism and nutrient-substrate regulation. In multi-receptor research, investigators examine how glucagon-pathway activity interacts with incretin signalling and whole-system energy balance.
Hepatic and energy-substrate signallingCombining receptor activities in one molecular design provides a way to investigate how incretin and glucagon signalling interact. The biological response depends on receptor distribution, tissue context and experimental conditions.
Retatrutide (LY3437943) is a 39-residue, GIP-based synthetic peptide. Its engineered sequence includes non-proteinogenic amino-acid substitutions and a lipid side chain attached at Lys17. The design combines receptor pharmacology with molecular modifications intended to influence stability and pharmacokinetic behaviour.
Reference identity values are literature descriptors and may vary by salt form or analytical convention. They do not verify the identity, purity, biological activity or quality of any specific sample. Confirm chemical identity using appropriate orthogonal analytical methods.
Sequence engineering and lipid conjugation are central to the molecule's design. The schematic below is an explanatory summary, not a synthesis protocol or a complete structural representation.
The peptide is based on a glucose-dependent insulinotropic polypeptide (GIP) sequence framework. Its single-chain architecture is engineered to engage three related class B G-protein-coupled receptors.
Published structural descriptions identify Aib substitutions at positions 2 and 20 and α-methyl-L-leucine at position 13. Such substitutions are used in peptide design to tune stability and receptor activity; effects depend on the full molecular context.
A C20 fatty diacid is linked to the Lys17 side chain through a spacer/linker architecture. Reversible albumin association is part of the reported design rationale for modifying circulation and exposure characteristics.
“39 amino acids” describes the peptide backbone length; it does not mean the entire conjugated molecule contains only 39 simple amino-acid units. Linker and lipid components also contribute to the molecular formula and mass.
Obesity and metabolic regulation are multi-organ phenomena. The three receptor systems are studied as connected signals, not as three independent switches.
Incretin signalling links nutrient intake with pancreatic hormone responses and other tissue-specific processes.
Glucagon signalling contributes to hepatic glucose production and the regulation of circulating energy substrates.
Research examines how these pathways interact across tissues, including glucose homeostasis, nutrient handling and energy balance.
This is a simplified conceptual map. It does not predict a clinical outcome or imply that receptor activation produces a uniform response across species, tissues or experimental models.
Retatrutide has been characterised as a unimolecular agonist with activity at GIPR, GLP-1R and GCGR. Published studies compare its activity with the endogenous ligands, but numerical potency depends on the receptor construct, assay platform, species and endpoint.
For that reason, this guide does not reproduce unverified EC50 values as universal constants. A meaningful comparison should cite the original assay, receptor species, cell system, readout and experimental conditions.
Published work has examined retatrutide as an investigational multi-receptor agonist. The following themes provide context for scientific reading, not instructions for use.
How does activity at GIP, GLP-1 and glucagon receptors differ, and how are those activities characterised in experimental systems?
How do incretin and glucagon pathways intersect in studies of nutrient handling, glucose homeostasis and energy-substrate regulation?
How do peptide sequence modifications and lipid conjugation influence molecular properties and receptor pharmacology?
Jastreboff AM et al. New England Journal of Medicine (2023). DOI: 10.1056/NEJMoa2301972.
A concise guide to terminology and research context.
Retatrutide has been described by its developer as an investigational medicine. Its research status and regulatory position may change; consult current regulator and developer information for updates.
Because it has agonist activity at three receptor targets: the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR).
No. This is an educational overview of published scientific concepts. It does not provide dosage, administration, treatment, diagnostic or medical advice.
A molecular formula describes the elemental composition of a defined chemical entity. It does not by itself establish identity, purity, biological activity or the quality of a specific sample.
The lipid side chain is part of the molecular design and is associated with reversible albumin binding. It is discussed in the literature as a way to influence exposure and pharmacokinetic properties, rather than as a stand-alone measure of biological potency.
No. EC50 values depend on assay design, receptor species and expression, cell background, endpoint and analysis method. Values should only be compared when the experimental systems are sufficiently aligned.
As of the latest developer information reviewed for this page (October 2026), retatrutide remains investigational and has not been approved by the FDA or other regulatory agencies. Regulatory status can change; check official sources for current information.
No. This page is scientific education only. It does not recommend human or veterinary use, establish a product's suitability for research, or verify any supplier, batch, quality system or regulatory status.
For general information enquiries, continue to the Peptide8 contact destination.